SO
CYCN icon

STRS Ohio’s Cyclerion Therapeutics CYCN Stock Holding History

STRS Ohio’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-315
Closed -$16K – 2184
2020
Q1 		$16K Hold
315
– – ﹤0.01% 1921
2019
Q4 		$17K Hold
315
– – ﹤0.01% 1989
2019
Q3 		$76K Hold
315
– – ﹤0.01% 1807
2019
Q2 		$72K Buy
+315
New +$89.1K ﹤0.01% 1870

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

STRS Ohio's CYCN Position: Q2 2020 in Review

STRS Ohio sold out of Cyclerion Therapeutics (CYCN) in Q2 2020, closing a stake of 315 shares — an estimated $16K sold.

STRS Ohio first reported a position in CYCN in Q2 2019 and held it in 4 quarters. The position peaked at $76K in Q3 2019. 74 funds tracked by Wall St. Rank hold CYCN as of Q2 2020.

  • STRS Ohio reported no remaining Cyclerion Therapeutics position as of Q2 2020 after selling out during the quarter.
  • STRS Ohio sold 315 Cyclerion Therapeutics shares in Q2 2020, an estimated $16K.
  • STRS Ohio first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 4 quarters.
  • STRS Ohio's Cyclerion Therapeutics position peaked at $76K in Q3 2019.
  • 74 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2020.

Based on STRS Ohio's 13F filing for Q2 2020, filed 23 Jul 2020.